Cytokinetics, Incorporated

CYTK

$5.60B

Mid Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO498 employees

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 30, 2026

11w

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

4 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date omecamtiv mecarbil (standard)

4/30/2026

For chronic heart failure. NDA filing. Extracted from SEC filing: 8-K

Source

🎯PDUFA

FDA PDUFA Date reldesemtiv (standard)

5/24/2026

For amyotrophic lateral sclerosis (ALS). NDA filing. Extracted from SEC filing: 8-K

Source

⭐Phase 3

Aficamten Phase 3 Results Expected

June 2026~Aficamten500

Primary completion for Aficamten trial (NCT06081894) in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Source

Phase 2

CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) Phase 2 Results Expected

September 2026~CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)60

Primary completion for CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) trial (NCT06793371) in Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Standard of Care

Phase 3

Heart Failure

Aficamten

Phase 3

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)

Phase 3

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Omecamtiv Mecarbil (OM)

Phase 3

Heart Failure

Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)

Phase 3

Obstructive Hypertrophic Cardiomyopathy (oHCM)

tirasemtiv

Phase 3

Amyotrophic Lateral Sclerosis (ALS)

Omecamtiv Mecarbil

Phase 3

Heart Failure With Reduced Ejection Fraction

Reldesemtiv

Phase 2

Amyotrophic Lateral Sclerosis

375 mg CK-2017357

Phase 2

Intermittent Claudication

Reldesemtiv 150 mg

Phase 2

Spinal Muscular Atrophy

25 mg Omecamtiv Mecarbil

Phase 2

Heart Failure With Reduced Ejection Fraction

SB-743921

Phase 2

Non-Hodgkin's Lymphoma

CK-3773274 (5 - 15 mg)

Phase 2

Hypertrophic Cardiomyopathy (HCM)

250 mg CK-2017357

Phase 2

Amyotrophic Lateral Sclerosis

CK-1827452 24mg and 6 mg iv infusion

Phase 2

Heart Failure

CK-2017357 (Part A)

Phase 2

Amyotrophic Lateral Sclerosis

CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

Phase 2

Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

CK-2017357

Phase 2

Amyotrophic Lateral Sclerosis

Omecamtiv Mecarbil Matrix F1 Formulation

Phase 2

Modified Release Oral Formulation

Riluzole 50 MG

Phase 2

Amyotrophic Lateral Sclerosis

CK-1827452

Phase 2

Heart Failure

Drug Name	Phase	Indication	Designations
Standard of Care	Phase 3	Heart Failure	-
Aficamten	Phase 3	Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy	-
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)	Phase 3	Obstructive Hypertrophic Cardiomyopathy (oHCM)	-
Omecamtiv Mecarbil (OM)	Phase 3	Heart Failure	-
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)	Phase 3	Obstructive Hypertrophic Cardiomyopathy (oHCM)	-
tirasemtiv	Phase 3	Amyotrophic Lateral Sclerosis (ALS)	-
Omecamtiv Mecarbil	Phase 3	Heart Failure With Reduced Ejection Fraction	-
Reldesemtiv	Phase 2	Amyotrophic Lateral Sclerosis	-
375 mg CK-2017357	Phase 2	Intermittent Claudication	-
Reldesemtiv 150 mg	Phase 2	Spinal Muscular Atrophy	-
25 mg Omecamtiv Mecarbil	Phase 2	Heart Failure With Reduced Ejection Fraction	-
SB-743921	Phase 2	Non-Hodgkin's Lymphoma	-
CK-3773274 (5 - 15 mg)	Phase 2	Hypertrophic Cardiomyopathy (HCM)	-
250 mg CK-2017357	Phase 2	Amyotrophic Lateral Sclerosis	-
CK-1827452 24mg and 6 mg iv infusion	Phase 2	Heart Failure	-
CK-2017357 (Part A)	Phase 2	Amyotrophic Lateral Sclerosis	-
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)	Phase 2	Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)	-
CK-2017357	Phase 2	Amyotrophic Lateral Sclerosis	-
Omecamtiv Mecarbil Matrix F1 Formulation	Phase 2	Modified Release Oral Formulation	-
Riluzole 50 MG	Phase 2	Amyotrophic Lateral Sclerosis	-
CK-1827452	Phase 2	Heart Failure	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

CYTK News